XBiotech Inc. (NASDAQ:XBIT) shot up 1.9% during trading on Thursday . The company traded as high as $15.15 and last traded at $14.78, with a volume of 544,058 shares traded. The stock had previously closed at $14.50.

A number of research firms recently commented on XBIT. Zacks Investment Research upgraded XBiotech from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research report on Tuesday, April 5th. Noble Financial restated a “buy” rating and set a $30.00 price objective (up from $24.00) on shares of XBiotech in a research report on Tuesday, June 28th.

The stock’s 50 day moving average price is $16.69 and its 200 day moving average price is $11.62. The company’s market cap is $510.48 million.

In related news, Director W Thorpe Mckenzie acquired 20,000 shares of XBiotech stock in a transaction on Thursday, May 26th. The stock was acquired at an average price of $13.96 per share, for a total transaction of $279,200.00. Following the purchase, the director now owns 3,898,600 shares of the company’s stock, valued at approximately $54,424,456. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. The Company primarily focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.